Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report

Hematopoietic stem cell transplantation (hsct) severely undermines the recipients' immune status and makes them prone to complications following viral infection. here, we report a 3-year-old boy with mucopolysaccharidosis type vi who acquired sars-cov-2 infection after hsct. the boy was diagnosed with sars-cov-2 during the post-transplant period (19 days after hsct) when dealing with acute graft versus host disease (gvhd). he was successfully treated with remdesivir and tocilizumab and recovered. well-timed treatment with tocilizumab might reduce the risk of invasive mechanical ventilation and death in patients with severe covid-19 pneumonia in the early post hsct period.